Demand for Veterinary Medicines in Russia Stabilized Throughout 2025

The Russian retail market for veterinary medicines not only expanded in 2025 but also broke away from its traditional seasonal pattern. According to analytical company RNC Pharma, the growing availability of new products helped smooth demand for animal medicines across the year.

Between January and November 2025, veterinary pharmacies and pet stores in Russia sold 257.1 million minimum dosage units (MDUs) of veterinary medicines. In physical terms, consumption increased by 13.4% year on year, while total retail spending rose by 16.9% to ₽45.6 billion, including VAT.

Analysts note that sales of veterinary medicines in Russia have historically peaked in spring. In 2025, however, physical consumption remained consistently high from March onward, with average monthly sales of around 24 million MDUs. This pattern differs noticeably from previous years and, according to RNC Pharma, reflects the expansion of the product range. In recent years, the market has seen the launch of medicines with peak demand extending into the summer months.

Stable demand over the year was largely supported by the strong performance of domestically produced veterinary medicines. Compared with January–November 2024, sales of Russian products grew by 36% in value terms and by 26% in physical volume. The domestic portfolio expanded by 166 SKUs, bringing the total assortment to around 3,400 product lines.

At the same time, the number of SKUs from foreign manufacturers declined by 65, falling to approximately 2,300 items. In the segment of imported veterinary medicines, physical demand dropped by 11% in MDUs, while sales value decreased by 0.8% in ruble terms. As a result, locally produced medicines accounted for more than 73% of retail sales by volume and 56% by value.

For January–November 2025, the retail market leader remained the U.S.-based Zoetis, holding a 12.3% share by value. Russia’s Ecopharm ranked second with 10.4%, followed by Slovenia’s KRKA at 10%. The top-10 ranking also changed over the year, with another Russian manufacturer, Vetbiochem, entering the group after doubling its sales. Growth was driven mainly by vaccines for companion animals, including Multikan, Multifel and Asterion, whose sales increased two- to threefold.

Among companies ranked in the top 20, the fastest revenue growth was recorded by Russia’s Vetpharmstandard. In the second half of 2024, the company launched the insectoacaricidal product Ticksfly, which quickly entered the top ten most popular veterinary medicines. As a result, Vetpharmstandard now ranks 13th among leading veterinary corporations.

Source: RNC Pharma